University of Salamanca at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
University of Salamanca takes part in 2 sessions at ASH 2026 in New Orleans. Its program centres on multiple myeloma. It covers BCMA-targeted bispecific antibodies from biology to real-world use, and tailoring treatment for newly diagnosed patients.
| Organization | ASH 2026 Attendance |
|---|---|
University of Salamanca Salamanca, Spain | |
Public university in Salamanca, Spain, one of Europe's oldest, with a medical school. | Symposium Fri Dec 11 7:00am–10:00am Anti-BCMA Bispecific Antibodies in Multiple Myeloma: From Biology to Real-World Implementation Bispecific antibodies targeting B-cell maturation antigen in myeloma, from mechanism and resistance to trial data, outpatient dosing, and infection prevention. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Translating Evolving Standards of Care in Newly Diagnosed Multiple Myeloma Into Individualized Treatment Strategies Choosing four-drug starting regimens for newly diagnosed myeloma, using residual disease tests to guide therapy, and managing new side effects. |
Instantly find 20 buyers from University of Salamanca
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction